What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)”In the company’s words, NCT03802799 on ClinicalTrials.gov
- Tested for
- Fragile X Syndrome
- Main trialPhase 2/3
- “ZYN002 is a pharmaceutically manufactured Cannabidiol that is developed as a clear gel that can be applied to the skin (called transdermal delivery). The gel will be applied to clean, dry, intact skin of the shoulders and/or upper arms. Participants from the ZYN2-CL-016 and ZYN2-CL-033 studies who meet the inclusion criteria and none of the exclusion criteria for study ZYN2-CL-017 are eligible. Parents/caregivers will apply the study gel twice daily for the 52-week treatment period.”In the company’s words, NCT03802799 on ClinicalTrials.gov
- Other names
- Cannabidiol Transdermal Gel
Other drugs for Fragile X Syndrome
- ZatolmilastTetra Discovery Partners · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- CTH120Connecta Therapeutics, S.L. · Phase 2
- MRM-3379Mirum Pharmaceuticals, Inc. · Phase 2
- SRX246Azevan Pharmaceuticals · Phase 2
- S247240Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Active, not recruiting | 30 Jun 2026 | Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | |
| Phase 3Completed | 29 Aug 2025 | Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome | |
| Phase 2/3Completed | 14 Jun 2020 | Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) | |
| Phase 2Completed | 9 Nov 2022 | Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026